CN104013676B - Buddleja officinalis and application of extract thereof in drug preparation - Google Patents
Buddleja officinalis and application of extract thereof in drug preparation Download PDFInfo
- Publication number
- CN104013676B CN104013676B CN201410279787.XA CN201410279787A CN104013676B CN 104013676 B CN104013676 B CN 104013676B CN 201410279787 A CN201410279787 A CN 201410279787A CN 104013676 B CN104013676 B CN 104013676B
- Authority
- CN
- China
- Prior art keywords
- flos buddlejae
- extract
- parts
- chronic obstructive
- obstructive pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 229940079593 drug Drugs 0.000 title abstract description 15
- 241000123846 Buddleja officinalis Species 0.000 title abstract description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 31
- 241000628997 Flos Species 0.000 claims description 90
- 239000000843 powder Substances 0.000 claims description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 61
- 239000007788 liquid Substances 0.000 abstract description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 238000000605 extraction Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 239000003208 petroleum Substances 0.000 abstract description 3
- 238000010992 reflux Methods 0.000 abstract description 3
- 241001113846 Loganiaceae Species 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 235000013311 vegetables Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 35
- 241000700159 Rattus Species 0.000 description 30
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 210000002460 smooth muscle Anatomy 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 206010036790 Productive cough Diseases 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 230000009325 pulmonary function Effects 0.000 description 10
- 210000000621 bronchi Anatomy 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 238000007654 immersion Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000003123 bronchiole Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000019504 cigarettes Nutrition 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 230000003448 neutrophilic effect Effects 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000004490 capsule suspension Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- 241000252335 Acipenser Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241001113925 Buddleja Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 201000009495 Hypotrichosis Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a natural vegetable mendicant and/or a new application of an extract thereof in the preparation of a drug for treating chronic obstructive pulmonary disease. The invention relates to buddleja officinalis and an application of extract thereof in the preparation of the drug for treating chronic obstructive pulmonary disease. The buddleja officinalis is flower bud, inflorescence or complete stool of loganiaceae plant buddleja officinalis, and is grinded to be used as a medicine; the extract is obtained via room-temperature digestion or heating reflux or supercritical liquid extraction after the buddleja officinalis is grinded; the solvent used by the extraction is liquid mixed by water and ethanol in any proportion, or liquid mixed by organic solvents such as diethyl ether, petroleum ether, chloroform and ethyl acetate in any proportion, or liquid CO2. Animal experiments and clinic experiments show that the pharmaceutical preparation prepared by the buddleja officinalis and the extract thereof do not have obvious untoward effects and toxic and side effects, and are capable of providing safe and efficient natural medicinal plant novel products for treating chronic obstructive pulmonary disease.
Description
Technical field
The invention belongs to technical field of Chinese medicines, and in particular to a kind of natural plant crude drugs and/or its extract are slow in treatment
New application in property obstructive pulmonary disease medicine.
Technical background
Chronic obstructive pulmonary disease (COPD, abbreviation chronic obstructive pulmonary disease) is a kind of disease being characterized with not fully reversible property flow limitation
Diseased state, flow limitation develops in progressive form, more relevant with the abnormal inflammatory reaction of gas to deleterious particle with pulmonary.It is one
Important chronic respiratory system diseasess are planted, number of patients is more, case fatality rate is high, because it is slowly developed, has a strong impact on patient
Work capacity and quality of life.According to WHO data displays, the whole world has threat of 600,000,000 populations in the face of chronic obstructive pulmonary disease,
The current the fourth-largest cause of disease of disease death in the world, China is per minute just to have 2.5 people to die from the disease, have every year 1000000 people because
This is dead.Nineteen ninety, COPD occupies the 12nd in the burden that disease is caused, the research knot subsidized by the World Bank/WHO
Fruit shows, it is contemplated that to the year two thousand twenty, and COPD will become the disease of worldwide the fifth-largest burden.
Chronic obstructive pulmonary disease (COPD) is common clinical, frequently-occurring disease, at present both at home and abroad western medical treatment primary disease with expectoration,
Airway patency is kept such as to remove expectorant medicine (mucolytic), bronchodilators, glucocorticoid Drug therapy and oxygen therapy, machinery
Ventilation etc. is based on therapy, although can to a certain extent delay the development of primary disease, but can not fundamentally change the prognosis of patient,
Curative effect is still unsatisfactory.
Because COPD is a kind of multifactor combined condition for causing, the Western medicine of any single-activity composition all cannot be reversed
The process of the COPD courses of disease, therefore, Chinese medicine of the exploitation with many active component, multiaction target spot will have very big potentiality and light
Prospect.
Flos Buddlejae Buddleja officinalis Maxim. exist《Chinese Pharmacopoeia》2010 editions contained functions with cure mainly for
" heat clearing away nourishing the liver, improving acuity of vision and removing nebula.For conjunctival congestion and swelling pain, many tear photophobia, nebula of looking unfamiliar film, hepatasthenia dim eyesight, blurring of vision." history tree
And the medicinal ancient books and records of each minority name race are used Flos Buddlejae as " nourishing the liver to improve visual acuity " medicine, are used especially as " ophthalmology panacea ".
Before this, there is the patent applied in many medicines with regard to Flos Buddlejae in terms of ophthalmology and liver is prepared
Application and document report, but there is no document report using Flos Buddlejae as the medicine for the treatment of pneumonopathy.
The content of the invention
It is an object of the invention to provide a kind of new opplication of Flos Buddlejae and/or its extract in pharmaceutical field.
The present invention relates to the application of Flos Buddlejae and/or its extract in the medicine for preparing treatment chronic obstructive pulmonary disease.
Flos Buddlejae of the present invention is loganiaceae plant Flos Buddlejae alabastrum, inflorescence or its Herb, and crushing is used as medicine, described
Extract be Flos Buddlejae crushing after room temperature extraction be either heated to reflux or supercritical extraction obtained in extract, extract
The solvent for being used is water and ethanol liquid miscible in any proportion；Or ether, petroleum ether, chloroform, ethyl acetate
Deng the liquid that organic solvent is miscible in any proportion；Or liquid CO2。
Described room temperature is extracted, is heated to reflux, supercritical extraction is prior art.
Flos Buddlejae of the present invention and/or its extract can make pharmaceutical preparation separately as main active,
Pharmaceutical preparation can also be made with other compositions collectively as main active.
Pharmaceutical dosage form of the present invention includes the medicine system of the different way of administration such as various oral, injections, tract, percutaneous
Agent.Can be raw material of the present invention with capsule made by corresponding pharmaceutic adjuvant Jing common process, tablet, granule, pill,
The compound preparation of externally-applied liniment, spray, injection etc., or raw material of the present invention and other Chinese crude drug compositions.
The invention provides the new opplication of Flos Buddlejae and/or its extract, provides new for chronic obstructive pulmonary disease treatment
Natural medicinal plant.Pharmaceutical preparation Jing animal experiments and clinical trial made by the present invention show without obvious adverse reaction and
Toxic and side effects, the natural medicinal plant new product that safe and efficient treatment chronic obstructive pulmonary disease can be provided for patient.
Drug safety test of the present invention
First, acute toxicity test
1 materials and methods
1.1.1 animal：The qualified cleaning grade Kunming mouse 40 of health, 18～22g of body weight, male and female half and half are cured by Kunming
University of section Experimental Animal Center is provided.
1.1.2 test medicine and its preparation：Flos Buddlejae capsule (preparation method is shown in embodiment 2, similarly hereinafter) is famous in Pharmaceutical by Yunnan to be had
Limit company provides, specification 0.5g/ grain.Take 40 Flos Buddlejae capsules and remove capsule shell, pour out medicated powder, 5min is ground in mortar
2% sodium carboxymethyl cellulose is gradually added into afterwards, and with for pasty state suspension, sticky, end level is 36%, is Flos Buddlejae capsule
Maximum concentration.
1.2 test method
Reference《Study of tcm new drug guide》(pharmacy, pharmacology, toxicology), in the laboratory of 22 DEG C of room temperature, repeatedly
Prerun mouse gavaging capsule 40g/kg (capsule suspension Cmax and maximum capacity), one week mouse toxicity of observation reacts and dead
Die situation, fail to measure capsule gavage LD50 value, therefore select mtd test.
Choose the qualified cleaning grade Kunming mouse of 20 health, male and female half and half, with gavage in capsule suspension 24h 3 times, are given
Medicine capacity is 0.2ml/10g body weight, then free water and is looked for food, and is observed one week, record mice appetite, body weight, position, is exhaled
Situations such as suction, righting reflex.
1.3 result of the test
Interior none death in 1 week of mouse stomach capsule suspension, change without exception of taking food and drink water, as shown in table 1.
Result after the mouse gavaging Flos Buddlejae capsule of table 1
In observation 7 days, medication dead mouse and obvious abnormal phenomena occur.Jing cervical dislocations are put to death and dissect every animal simultaneously
Compare with normal mouse, under bore hole, the discovery without exception such as the heart, liver, spleen, lung, kidney, brain.
This result of the test, mouse gavaging Flos Buddlejae capsule Cmax and maximum volume, i.e. 21.6g/kg body weight, are human body
288 times of dose, have no that toxicity occurs.
Medicine effect test of the present invention
2nd, impact of the Flos Buddlejae capsule to chronic obstructive pulmonary disease model rat airway inflammation and pathologic state colony
1 materials and methods
1.1 reagents and medicine Flos Buddlejae capsule：There is provided by Yunnan Mingyang Pharmaceutical Co., Ltd..Medicated cigarette：Commercially available Red River board is fragrant
Cigarette, tar content 13mg, gas nicotine amount 1.3mg.Lipopolysaccharide (LPS)：Sigma Co., USA.Pentobarbital sodium：The western Tang in Shanghai is biological
Science and Technology Ltd..Wright's staining liquid：Qingdao Hai Bo biotech companies.
1.2 instrument 5804R low temperature supercentrifuges (German eppendorf companies).Olympuss CH30 optical microscopes.
RM2016 type cycle type paraffin section agent (Shanghai Lai Ka Instrument Ltd.).Desk type constant-temperatureoscillator oscillator (contains prestige test in Jintan City
Instrument plant).
1.3 packets and method healthy SD rat 47, ♂, body weight (203 ± 18) g, purchased from Kunming Medical University's laboratory animal
Center.Rat is randomly divided into into 5 groups, Normal group 7, model group and high, medium and low per group of the metering group each 10 of Flos Buddlejae capsule
Only.The 1st, 14 days in model copy, in addition to Normal group, after remaining various use pentobarbital sodium anesthetized rat, open it
Cervical region, exposes trachea, and each 0.2ml of lipopolysaccharide (LPS), (200 μ g/200ml), in skin are injected to tracheal strips with 1ml syringes
Wound instills penicillin injection liquid, then skin suture and with iodine tincture cotton balls sterile working, and the 2nd～13 day, 15～28 days often
Morning day smokes Red River board medicated cigarette 0.5h in 75L closed boxs.(from the beginning of the 3rd day of modeling), Normal group is gavaged for administration
0.9% normal saline 10mlkg, 1 time/d；Model group gavages 0.9% normal saline 10mlkg, 1 time/d；The high agent of Flos Buddlejae capsule
Amount group gavages Flos Buddlejae capsule (equivalent to 10 times of clinical adult human dose)：22.8g/kg,2.28g/ml；Agent in Flos Buddlejae capsule
Amount group gavages Flos Buddlejae capsule (equivalent to 5 times of clinical adult human dose)：11.4g/kg,11.4g/ml；Low dose of Flos Buddlejae capsule
Amount group gavages Flos Buddlejae capsule (equivalent to 2.5 times of clinical adult human dose)：5.7g/kg,0.57g/ml.5 groups of equal continuous gavages
28 days, gavage terminated the 2nd day, determined indices.
1.4 observation index
1.4.1 the mobility of ordinary circumstance observation rat, the sensitivity reacted to external world and fur gloss, diet, drinking-water,
Body constitution, death condition.
1.4.2 bronchoalveolar lavage fluid (BALF) inflammatory cell count femoral artery sacrificed by exsanguination rat, opens breast knot and pricks it
Right principal bronchuss, with the normal saline 5ml containing the heparin sodium point of left lung of 2 lavations, collect bronchoalveolar lavage fluid, by BALF
It is mixed, takes 0.1ml and add the dilution of equivalent numeration of leukocyte liquid.Counted with blood cell counting plate, remaining BALF centrifuges
2000r/min is centrifuged 10min, precipitate smear, to do after Wright's staining and count under light microscopic 400 leukocyte and carry out cell divide meter
Number.
1.4.3 Leukocyte Counts and classification takes femoral artery blood, and smear does and count under light microscopic after Wright's staining 400 in vain
Cell carries out classified counting of leucocyte.
1.4.4 at broncho-pulmonary Histomorphological rat after death, superior lobe of left lung position is taken in 10% neutral formal
It is fixed in woods solution.Ethanol serial dehydration, dimethylbenzene transparent specimen, waxdip, embedding, section, HE dyeing, under optical microscope
Tissues observed morphological change.
The all experimental datas of 1.5 statistical procedures adopt SPSS11.5 software kit statistical analysiss.
2 results
2.1 ordinary circumstance normal rats are vivaciously active, and fur is smooth, and build is fat, and breathing is steady；Model group rats are lived
Momentum is gradually decreased, expression atrophy, hogback curling oneself up, hypotrichosis, erects hair, and matt, appetite is reduced, and is slow in action, and build is thin
It is little, cough frequency was started from the 18th day and is made, sneeze frequency is made, and later stage exaggerated respiration is rapid, meets the performance of syndrome of deficiency of lung qi；Flos Buddlejae
The high, medium and low dosage group rat of capsule is between matched group and model group.
Total white blood cellses, lymph in 2.2 bronchoalveolar lavage fluid (BALF) inflammatory cell count model group BALF are thin
Born of the same parents' number, neutrophilic granulocyte number are substantially more compared with Normal group, and difference has significance (P ＜ 0.05).In three groups for the treatment of group BALF
Total white blood cellses, lymphocyte number, neutrophilic granulocyte number substantially reduce compared with model group, difference has significance (P ＜ 0.01, P
＜ 0.05), the results are shown in Table 2.
The each group rat Other nucleated cells differential count of table 2 and classification are compared
Compare with matched group, * P<0.05；Compare with model group,△P<0.05,▲P<0.01。
2.3 Leukocyte Counts and disaggregated model group blood leukocytes sum, lymphocyte number, neutrophilic granulocyte number are obvious
Many compared with Normal group, difference has significance.Three groups for the treatment of group's total white blood cellses, lymphocyte number, neutrophilic granulocyte numbers are bright
Aobvious to reduce compared with model group, difference has significance (P ＜ 0.01, P ＜ 0.05), no significant difference between Flos Buddlejae capsule various dose group
(P ＞ 0.05), the results are shown in Table 3.
The each group rat Other nucleated cells differential count of table 3 and classification are compared
Compare with matched group, * P<0.05；Compare with model group,△P<0.05,▲P<0.01。
2.4 broncho-pulmonary tectologies change control rats trachea-bronchial epithelial cell alveolar structure completely, on bronchioless
Without deformation, without exudate, alveolar septum is without thickening for alveolar intracavity for chrotoplast.Model group pathologic shows the characteristic of COPD
Change, in addition to having the narrow deformation of bronchioless, focal alveolar inflammation performance also occur.The big amount lymphocyte leaching of tube wall
Profit, bronchioless adjacent domain alveolar septum lymphocyte and neutrophil infiltration, change region also common focal destruction, multiple
Alveolar mutually merges, and small part bronchioless tube wall is shown in smooth muscle collagenous tissue hypertrophy, while petty action blood vessel wall also has increasing
Thickness, vascular endothelial cell and proliferation of smooth muscle.The characteristic pathological that the high, medium and low dosage group of Flos Buddlejae capsule also has COPD changes,
But universal light compared with model group, wherein respiratory bronchus luminal stenosis and obturation slightly mitigate compared with model group, lamina propria hyperemia water
It is swollen to mitigate, though tube wall has lymphocytic infiltration, significantly reduce compared with model group, bronchioless and petty action blood vessel wall smooth muscle and glue
Fibril hamartoplasia also makes model group substantially mitigate.Wherein, Flos Buddlejae capsule in high dose group relatively in, low dose group COPD symptom
Mitigate obvious.
3 conclusions
Flos Buddlejae capsule is high, middle dose group can suppress or mitigate COPD rat airway inflammatory reactions, and reduces inflammation and draw
The lung injury for rising.
3rd, therapeutical effect of the Flos Buddlejae capsule to chronic obstructive pulmonary disease
1 material and method
1.1 reagents and medicine Flos Buddlejae capsule：There is provided by Yunnan Mingyang Pharmaceutical Co., Ltd..Medicated cigarette：Commercially available Red River board is fragrant
Cigarette, tar content 13mg, gas nicotine amount 1.3mg.Lipopolysaccharide (LPS)：Sigma Co., USA.Pentobarbital sodium：The western Tang in Shanghai is biological
Science and Technology Ltd..
2.2 instrument test animal lung function analysis systems (Beijing Space new ideas softcom limited)；Olympuss
CH30 optical microscopes；RM2016 type cycle type paraffin section agent (Shanghai Lai Ka Instrument Ltd.).
1.3 packets and method healthy SD rat 50, ♂, body weight (200 ± 23) g, purchased from Kunming Medical University's laboratory animal
Center.Rat is randomly divided into into group 5 groups, i.e. Normal group, model group and the high, medium and low metering group of Flos Buddlejae capsule, per group each
10.Animal model and medication are with test two.
1.4 observation index
1.4.1 at bronchus Morphological measurement rat after death, superior lobe of left lung position is taken in 10% neutral formalin solution
Middle fixation.Ethanol serial dehydration, dimethylbenzene transparent specimen, waxdip, embedding, section, HE dyeing measures little with image analysis system
Bronchus caliber, tube wall and smooth muscle layer thickness
1.4.2 lung function testses are put in people's case with pentobarbital sodium anesthetized rat, tracheal intubation, and record rat 8 is autonomous
Breathing cycle, airway pressure (P), volume (V) change are obtained, be accordingly calculated lung expiratory resistance (Re), pulmonary aspiration resistance
(Ri).Afterwards, quickly injection 6mL air causes rat passively to deeply breathe to Jing tee Ts into rat airway, you can measure is exerted oneself
Vital capacity (FVC), the 0.3rd forced expiratory volume (FEV0.3, corresponding to the FEV1 of people), draw its ratio FEV0.3/FVC.
1.51.5 all experimental datas of statistical procedures adopt SPSS11.5 software kit statistical analysiss.
2 results
2.1 bronchus Morphological measurements randomly select bronchia more regular in the section of bronchus HE, and each specimen selects 3
～6 bronchus cross-sectional areas, are calculated using image analysis system：The tube wall gross area (WAt)=air flue outer wall encloses face
Area (Ai) on the inside of product (Ao)-tube wall；Smooth muscle layer area (WAsm)=smooth muscle layer outside area (Asmo)-smooth muscle
Layer inner side area (Asmi).It is standardized with girth in tube wall (Pi), as a result with the tube wall area (WAt/Pi) of unit length
Pipe thickness is represented, smooth muscle layer thickness is represented with the smooth muscle layer area (WAsm/Pi) of unit length.Results model group rat
Bronchia wall and smooth muscle layer substantially thicken (P ＜ 0.01) compared with matched group, and with emophysematous generation, illustrate COPD rats
There is the change of small airway organizational structure.Jing after treatment, Flos Buddlejae capsule height, middle dose group rat bronchia wall and smooth muscle
Thickness degree is significantly reduced (P ＜ 0.05) compared with model group.Bronchus Morphological measurement the results are shown in Table 4.
The bronchus Morphological measurement result of table 4
Compare with matched group, * P<0.01；Compare with model group,△P<0.05,▲P<0.01。
2.2 Pulmonary functions compare with Normal group, and model group rats FEV0.3/FVC significantly reduces (P<0.01),
Re, Ri significantly raise (P<0.01), hints model rat has airflow obstruction.Compare with model group, Flos Buddlejae capsule is high, middle dosage
Group rat FEV0.3/FVC significantly raises (P<0.01), ReRi significantly reduces (P<0.01).Pulmonary function measurement result is shown in Table
5。
The pulmonary function measurement result of table 5
Compare with matched group, * P<0.01；Compare with model group,△P<0.05,▲P<0.01。
3 conclusions
Flos Buddlejae capsule is high, middle dose group can substantially suppress COPD rat small airway tube walls and smooth muscle layer is thickened, and rises
High rat FEV0.3/FVC, reduces rat Re, Ri.Illustrate that the Chinese medicine can improve COPD pulmonary functions, point out the medicine to pass through
COPD airway remodelings are suppressed to reach the purpose for preventing decline in pulmonary function.
Clinical data
4th, Flos Buddlejae capsule for treating chronic obstructive pulmonary disease clinical observation
1 data and method
1.1 diagnostic criteria
1.1.1 Western medicine diagnostic criteria was with reference to Chinese Medical Association in 2007《Chronic obstructive pulmonary disease diagnosis and treatment guide》Diagnostic criteria
And severity Scaling standard related content is formulated.
1.1.2 TCM syndrome diagnostic criteria traditional Chinese medical science deficiency of both the lung and kidney and asthenia of pulmonosplenic qi reference《New Chinese medicine clinical research is instructed
Principle》And《Diagnostics of Chinese Medicine》Relevant content is formulated.
1.2 inclusive criterias (1) meet chronic obstructive pulmonary disease diagnostic criteria；(2) in meeting Syndrome Differentiation of Traditional Chinese Medicine standard
Deficiency of both the lung and kidney and asthenia of pulmonosplenic qi amphitypy；(3) known the inside story consenter.
1.3 85 years old 18 years old or ﹥ case exclusion standard (1) ages ﹤；(2) merging Severe Respiratory Failure person, acute attack stage,
Concurrent infection person；(3) other serious organic disease persons are merged；(4) psychotic；(5) patient compliance is poor, it is impossible to press
When, on request medication and check person, the infull person of record material；(6) to drug allergy person used.
1.4 physical data will be diagnosed as COPD67 example patients and be randomly divided into 2 groups, matched group 32, wherein, man 18, female
14；40～70 years old age；The course of disease 3～21 years, average course of disease 15 years；Wherein severity extent I grade 9, II grade 17.III grade 6
Example.Treatment group 35, wherein, man 20, female 15；40～72 years old age；The course of disease 3～22 years, average course of disease 16 years；It is wherein sick
Feelings degree I grade 10, II grade 19.III grade 6.Have at aspects such as gender's composition, age, the course of disease, the state of an illness between two groups
Comparability, without significant difference (P ＞ 0.05).
1.5 Therapeutic Method matched groups are based on bronchodilator, resolving sputum and oxygen therapy.Bronchodilator is with aminophylline
Based on (Shandong XinHua Pharmacy stock Co., Ltd, specification 0.1g × 100 piece), 0.1g, orally, tid.Resolving sputum is with ambroxol hydrochloride
Based on (Yantai Dayang Pharmaceutical C0. Ltd, specification 30mg × 20 piece), 30, orally, tid.The oral mist Air Bladder pseudosciaenae seu Acipenser capsule for the treatment of group, often
Secondary 3,3 times a day, and two groups of courses for the treatment of are 3 months.
1.6 observation index coughs, expectoration, asthma symptom and pulmonary function
1.7 efficacy determination references《Chronic obstructive pulmonary disease diagnosis and treatment guide》Intend with regard to chronic obstructive pulmonary disease diagnosis and treatment specification
It is fixed.Clinic control：Cough, expectoration, asthma symptom disappear substantially, normal pulmonary function；It is effective：Cough, expectoration, asthma symptom are obvious
Mitigate, pulmonary function mitigates 2 grades；Effectively：Cough, expectoration, asthma symptom mitigate, and pulmonary function mitigates 1 grade；It is invalid：Cough, expectoration,
Asthma symptom and pulmonary function are without change or deterioration.
2 results
2.1 total effectses compare the treatment through 3 months, and two groups of total effectses the results are shown in Table 6.
6 two groups of comparitive studies (example) of table
Two groups of total effective rate comparing differences are statistically significant (* P ＜ 0.05)
2.2 individual event symptom comparitive studies are shown in Table 5,6,7.From table 5,6,7, treatment group is with matched group in cough, expectoration
Improvement in symptom is without significant difference (P ＞ 0.05).On the alleviation of asthma improves, treatment group is anxious compared with matched group time lengthening
Property attack times reduce, movable mass significantly improves (P ＜ 0.05).
7 two groups of individual event symptom (cough) comparitive studies of table
Two groups of total effective rate comparing differences are not statistically significant (P ＞ 0.05)
8 two groups of individual event symptom (expectoration) comparitive studies of table
Two groups of total effective rate comparing differences are not statistically significant (P ＞ 0.05)
9 two groups of individual event symptom (asthma) comparitive studies of table
Two groups of total effective rate comparing differences are statistically significant (* P ＜ 0.05)
2.3 untoward reaction situations are during observation, and treatment group patient is uncomfortable without subjectivity, after matched group few patients medication
There is xerostomia phenomenon.Hepatic and renal function, electrocardiogram etc. are showed no abnormal change.
Specific embodiment
The present invention is of the invention come detailed explanation and description by following medicine preparation embodiments, however, the present invention is not
It is limited to these embodiments.
Embodiment 1：Flos Buddlejae tablet
Formula：1000 parts of Flos Buddlejae, 3 parts of starch, 20 parts of Lactose, 15 parts of carboxymethyl starch sodium part, 4 parts of Pulvis Talci.
Preparation method：800 parts of Flos Buddlejae alabastrum is taken, decocts secondary by decocting method with drinking water, 1 hour every time, merging decocting liquid (or
Flos Buddlejae coarse powder is taken, the aquiferous ethanol with variable concentrations is secondary in 40 DEG C of immersions, 6～8 hours every time, merges soak), concentration
Decocting liquid (or soak) dry, pulverize into fine powder standby into thick paste in 55 DEG C～65 DEG C.Take 200 parts of Flos Buddlejae inflorescence, direct powder
Fine powder is broken into, is mixed with aforementioned Flos Buddlejae extract fine powder, Lactose, carboxymethyl starch sodium, with starch slurry adhesive is made, made
Grain, is dried, plus lubricant Pulvis Talci, and tabletting is obtained final product.
Embodiment 2：Flos Buddlejae capsule
Formula：1000 parts of Flos Buddlejae, 100 parts of starch.
Preparation method：700 parts of Flos Buddlejae alabastrum and inflorescence are taken, coarse powder is ground into, secondary with the extraction of acetone room temperature, for the first time 48 is little
When, second 40 hours, merge lixiviating solution, acetone is reclaimed, the thick paste after concentration is standby.300 parts of Flos Buddlejae alabastrum and inflorescence are taken,
Fine powder is directly ground to, is mixed homogeneously with aforementioned Flos Buddlejae extract thick paste, in 60 DEG C～70 DEG C fine powder is dry, pulverize into, with
100 parts of starch is mixed, encapsulated to obtain final product.
Embodiment 3：Flos Buddlejae capsule
Formula：1000 parts of Flos Buddlejae, 150 parts of starch.
Preparation method：800 parts of Flos Buddlejae Herb is taken, coarse powder is ground into, soaks secondary with 60% ethanol, 12～14 hours every time,
Merge immersion, reclaim ethanol, be condensed into thick paste standby.200 parts of Flos Buddlejae alabastrum and inflorescence are separately taken, fine powder is directly ground to, with
Aforementioned thick paste is mixed, and in 55 DEG C～65 DEG C fine powder is dry, pulverize into, is mixed with 150 parts of starch, loads capsule.
Embodiment 4：Flos Buddlejae granule
Formula：1000 parts of Flos Buddlejae, 10 parts of dextrin, 20 parts of Lactose.
Preparation method：800 parts of Flos Buddlejae Herb is taken, coarse powder is ground into, with petroleum ether and ether mixed liquor (3 ﹕ 1) room temperature extraction two
It is secondary, 40 hours for the first time, second 35 hours, merge lixiviating solution, organic solvent is reclaimed, the thick paste after concentration is standby.Take close illiteracy
200 parts of flower alabastrum and inflorescence, are directly ground to fine powder, mix homogeneously with aforementioned Flos Buddlejae extract thick paste, in 60 DEG C～70 DEG C
Fine powder is dry, pulverize into, is stirred with 10 parts of dextrin, 20 parts of Lactose, make granule, be drying to obtain.
Embodiment 5：Flos Buddlejae pill
Formula：1000 parts of Flos Buddlejae, 110 parts of refined honey.
Preparation method：800 parts of Flos Buddlejae Herb is taken, selection, washing dry, pulverize into fine powder in 60～65 DEG C, load extraction
Kettle, excludes all gas impurity in kettle, then supercritical fluid CO2 (31.05 DEG C of temperature ﹥, pressure ﹥ 7.39MP) injections are extracted
Kettle, soluble component is dissolved in medical material in extraction kettle, flows into from extraction kettle top dissolved with the Compressed CO_2 gas of extraction of substance
Separating still, blood pressure lowering, soluble component is separated out；Precipitate be dry, pulverize into into fine powder in 55 DEG C～65 DEG C standby.Take 200 parts it is close
Flos Buddlejae alabastrum and inflorescence, are ground into fine powder, mix homogeneously with fine powder made by supercritical extract, plus 110 parts of refined honeys are fitted with water
Amount, general ball is made water-honeyed pill, is obtained final product.
Embodiment 6：Flos Buddlejae liniment
Formula：1000 parts of Flos Buddlejae, 200 parts of glycerol.
Preparation method：1000 parts of Flos Buddlejae Herb is taken, decocts secondary by decocting method with distilled water, 1 hour every time, merge decocting liquid
(or Flos Buddlejae coarse powder is taken, the aquiferous ethanol with variable concentrations is secondary in 40 DEG C of immersions, 6～8 hours every time, merges soak),
Relative density 1.1～1.2, plus qdx ethanol are concentrated into, are stirred, stood, filtration, filtrate recycling ethanol, cold preservation 24 hours, filter
Cross, filtrate glycerol adding is mixed and obtains final product.
Embodiment 7：Flos Buddlejae spray
Formula：1000 parts of Flos Buddlejae, 50 parts of ethyl hydroxybenzoate.
Preparation method：1000 parts of Flos Buddlejae Herb is taken, decocts secondary by decocting method with distilled water, 1 hour every time, merge decocting liquid
(or Flos Buddlejae coarse powder is taken, the aquiferous ethanol with variable concentrations is secondary in 40 DEG C of immersions, 6～8 hours every time, merges soak),
Relative density 1.1～1.2, plus qdx ethanol are concentrated into, are stirred, stood, filtration, filtrate recycling ethanol, cold preservation 24 hours.Filter
Cross, plus ethyl hydroxybenzoate, it is mixed, plus distilled water is obtained final product.
Embodiment 8：Flos Buddlejae injection
Formula：1000 parts of Flos Buddlejae, benzyl alcohol 10ml, 8 parts of Sodium Chloride.
Preparation method：1000 parts of Flos Buddlejae alabastrum and inflorescence are taken, decocts secondary by decocting method with distilled water, 1 hour every time, merge water
Decocting liquid (or Flos Buddlejae coarse powder is taken, the aquiferous ethanol with variable concentrations is secondary in 40 DEG C of immersions, 4～6 hours every time, merges immersion
Liquid), relative density 1.1～1.2, plus qdx ethanol are concentrated into, stir, cold preservation, precipitation, filtration, filtrate recycling ethanol, concentration
To relative density 1.05～1.06, then add ethanol to alcohol content up to 80%, cold preservation filtration, filtrate recycling ethanol to without alcohol taste, plus
Benzyl alcohol, Sodium Chloride, stirring and dissolving injects water to 1000ml, is filtered with G4 sintered glass funnels, and embedding is in the peace of 2ml
In training, 100 DEG C of sterilizings are obtained final product for 30 minutes.
Embodiment 9：Compound preparation 1
Formula：350 parts of Flos Buddlejae, 50 parts of Flos Lonicerae, 240 parts of Flos Farfarae.
Preparation method：Take 250 parts of Flos Buddlejae Herb, 240 parts of Flos Farfarae.It is secondary with drinking water decoction, 2 hours every time, merge water
Decocting liquid (or Flos Buddlejae, Flos Farfarae coarse powder are taken, the aquiferous ethanol with 60% concentration is secondary in 40 DEG C of immersions, 6～8 hours every time, closes
And soak), decocting liquid or soak are condensed into into thick paste, fine powder is dry, pulverize in 55 DEG C～65 DEG C, with 100 portions of Flos Buddlejaes
Alabastrum and inflorescence fine powder, 50 parts of Flos Lonicerae fine powders are mixed, encapsulated to obtain final product.
Embodiment 10：Compound preparation 2
Formula：550 parts of Flos Buddlejae, 390 parts of Rhizoma Chuanxiong, 160 parts of Rhizoma Coptidis, 150 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), 260 parts of Radix Salviae Miltiorrhizae.
Preparation method：Take Flos Buddlejae alabastrum and 450 parts of inflorescence, 390 parts of Rhizoma Chuanxiong, 160 parts of Rhizoma Coptidis, 150 parts of Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Salviae Miltiorrhizae 260
Part, decocted with drinking water secondary, 2 hours every time, (or to take Flos Buddlejae, Rhizoma Chuanxiong, Rhizoma Coptidis, Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens), Radix Salviae Miltiorrhizae thick to merge decocting liquid
Powder, the aquiferous ethanol with 60% concentration is secondary in 40 DEG C of immersions, 6～8 hours every time, merges soak), concentration decocting liquid (or leaching
Bubble liquid) into thick paste, fine powder is dry, pulverize in 55 DEG C～65 DEG C, it is mixed with 100 parts of Flos Buddlejae alabastrums and inflorescence fine powder, fill glue
Capsule is obtained final product.
Above description is the general description of the present invention.According to circumstances or it is actually needed, the change of form can be carried out and waited
The replacement of value, although herein using specific term, but these terms are intended to description, rather than for the purpose for limiting.Ability
Field technique personnel can make various changes or modifications to the present invention, and these equivalent form of values equally fall within the application claims
Within book limited range.
Claims (1)
1. the application of Flos Buddlejae and its extract in the medicine for preparing treatment chronic obstructive pulmonary disease, takes Flos Buddlejae alabastrum and flower
700 parts of sequence, is ground into coarse powder, and secondary, 48 hours first times are extracted with acetone room temperature, second 40 hours, merges lixiviating solution, returns
Acetone is received, the thick paste after concentration is standby；300 parts of Flos Buddlejae alabastrum and inflorescence are taken, fine powder is directly ground to, is carried with aforementioned Flos Buddlejae
Thing thick paste mix homogeneously is taken, in 60 DEG C～70 DEG C fine powder is dry, pulverize into, 100 parts are mixed with starch, encapsulated to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279787.XA CN104013676B (en) | 2014-06-20 | 2014-06-20 | Buddleja officinalis and application of extract thereof in drug preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279787.XA CN104013676B (en) | 2014-06-20 | 2014-06-20 | Buddleja officinalis and application of extract thereof in drug preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104013676A CN104013676A (en) | 2014-09-03 |
| CN104013676B true CN104013676B (en) | 2017-05-03 |
Family
ID=51430859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410279787.XA Active CN104013676B (en) | 2014-06-20 | 2014-06-20 | Buddleja officinalis and application of extract thereof in drug preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104013676B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104957594A (en) * | 2015-06-29 | 2015-10-07 | 梁海林 | Preparation method of buddleja officinalis concentrated liquid |
-
2014
- 2014-06-20 CN CN201410279787.XA patent/CN104013676B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 基于文本挖掘技术的慢性阻塞性肺疾病临床用药规律分析;展俊平等;《中国中医药信息杂志》;20111231;第18卷(第12期);第27-30页 * |
| 密蒙花化学成分及生物活性研究进展;郭雷等;《食品研究与开发》;20120731;第33卷(第7期);第222-225页 * |
| 密蒙花研究进展;崔颖等;《甘肃中医学院学报》;20100430;第27卷(第2期);第65-68页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104013676A (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN104800236B (en) | Asarum total polysaccharide extractive and its extracting method and application with antitussive activity | |
| CN102579560A (en) | Preparation method of Chinese angelica and astragalus mongholicus mixture aqueous extract, as well as application in intervening in pulmonary fibrosis | |
| CN101849987B (en) | Preparation of Chinese angelica and astragalus root mixture ethanol extract and aqueous extract and application in intervening in pulmonary fibrosis | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN104013676B (en) | Buddleja officinalis and application of extract thereof in drug preparation | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN100444849C (en) | New use of tribulus terrestris extraction | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN104127544B (en) | The application in preparing medicine of Murraya tetramera Huang and extract thereof | |
| CN104324089A (en) | Rhubarb total anthraquinone being stable and uniform in proportion of various components and composition thereof used in jaundice-eliminating treatment of viral hepatitis type B | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN103110100A (en) | Korean medical healthcare food composition as well as preparation method and application thereof | |
| CN107007702A (en) | A kind of Chinese medicine composition and its preparation for treating osteoarthropathy | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN104547105A (en) | Agent for reducing blood glucose | |
| CN109771632A (en) | A kind of pharmaceutical composition and its preparation method and application for treating stable phase of chronic obstructive pulmonary disease | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| CN102058668A (en) | Traditional Chinese medicinal preparation for treating primary thrombocytopenia | |
| CN102861302B (en) | Traditional Chinese preparation for treating benign prostatic hyperplasia and preparation method for traditional Chinese preparation | |
| CN105250340A (en) | Preparation method and application of Myricaria germanica(L.)Desv. extract | |
| CN106492064A (en) | A kind of Chinese medicinal granule for treating children's bacterial infection diarrhoea | |
| CN107233540A (en) | A kind of Chinese medicine composition for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200819 Address after: 650200 Da Cun Xiao Changshan, osanqiao sub district office, Guandu District, Kunming City, Yunnan Province Patentee after: Yunnan Sunsail Pharmaceutical Co.,Ltd. Address before: 650051, Yunnan, Kunming province Qingnian Road Panlong 297 New Youth commercial and residential buildings Patentee before: Wen Xianmin |
|
| TR01 | Transfer of patent right |